Abstract: Kidney diseases are complex with several different etiologies and underlying associated pathophysiology. Globally there  are various screening methods for detection of various kidney diseases and intervention. Various screening methods are renal tissue biopsy, urine tests and serum specific protein assays. By using  spectrum of biomarkers, one can evaluate renal health and precise classification and analysis of various biomarkers helps in determining the site and extent of kidney injury.  So there is need to generate multidimensional data sets from genomics, blood, urine and kidney tissue samples for kidney patients, that will help in great research progress in understanding the pathogenesis of tubular damage,  novel biomarkers and treatments in kidney patients. This review aims to gather information on the use of novel kidney biomarkers (Kim-1, NGAL, microRNA, IL-17, IL-22, IL-18, uromodulin, NAG, NAGL, TIMP-2 ) in various kidney diseases. We have highlighted usefulness of these biomarkers in predicting tubular and/or glomerular injury in kidney diseases patients and showed their clinical applicability, accuracy, and cost-effectiveness in clinical practice.